Rosiglitazone - Preclinical Efficacy
In rodent models of obesity, insulin resistance and/or Type 2 diabetes
- Increased insulin sensitivity in liver, skeletal muscle and adipose tissue
- Improved glycemic control without causing hypoglycemia
- Lowered plasma concentrations of free fatty acids and triglycerides
- Protected against pancreatic ?-cell insulin depletion